top of page
Buscar

FDA grants accelerated approval to Nuvalent's Nelkarmi for previously treated ALK-positive lung cancer

Foto del escritor: nuaxia
nuaxia
hace 6 minutos
2 min de lectura

Nuvalent's Nelkarmi has received FDA accelerated approval for previously treated ALK-positive advanced lung cancer, offering another targeted treatment option for patients whose disease has progressed after earlier therapies.


On 17 November 2026, the US Food and Drug Administration granted accelerated approval to Nelkarmi (neladalkib) for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer following specified prior ALK inhibitor treatment, with previous platinum chemotherapy additionally required for one eligible treatment-history group.


In the ALKOVE-1 trial, objective response rates were 49% among patients previously treated with alectinib and 32% in a more heavily pretreated cohort; the accelerated approval is based on tumour response and response duration rather than established overall-survival benefit, and continued authorisation may depend on confirmatory evidence.

Field

Content

Company

Nuvalent

Medicine

Nelkarmi (neladalkib)

Regulatory Authority

US Food and Drug Administration

Approval Date

17 November 2026

Approval Type

Accelerated approval

Therapeutic Area

Oncology

Indication

Locally advanced or metastatic ALK-positive non-small cell lung cancer

Molecular Target

ALK

Eligible Patients

Adults meeting specified prior ALK inhibitor treatment requirements; platinum chemotherapy additionally required for one treatment-history group

Treatment Setting

Previously treated advanced or metastatic disease

Supporting Study

ALKOVE-1

Response Rate After Alectinib

49% objective response rate

Response Rate in Heavily Pretreated Cohort

32% objective response rate

Approval Evidence

Objective response rate and duration of response

Regulatory Limitation

Overall-survival benefit has not been established by the evidence described

Confirmatory Requirements

Continued accelerated approval may depend on verification of clinical benefit

Primary Source

https://www.fda.gov/drugs/cancer-approvals/fda-grants-accelerated-approval-neladalkib-previously-treated-locally-advanced-or-metastatic-alk


Discover how nuaxia can support your next medical education initiative:

 
 
 

Comentarios

Obtuvo 0 de 5 estrellas.
Aún no hay calificaciones

Agrega una calificación
bottom of page